May 19th, 2025Video Tribute to Mike Snyder We invite you to watch a video tribute to Mike Snyder, who passed away on April 26. Description: Mike Snyder a Founding board member of the Chondrosarcoma Foundation shares his life journey, challenges with this ultra...

May 12th, 2025The Chondrosarcoma (CS) Foundation will commemorate its fifth anniversary by continuing to educate the public about this rare bone cancer, advocate for patients fighting the disease and will report on their global natural history study. On May...

May 1st, 2025It is with a broken heart that I report to you the passing of my dear friend and founding foundation board member: Mike Snyder. In his case it was not chondrosarcoma that took his life but he passed away from a second heart attack this past...

April 11th, 2025John Gross, M.D. is a Faculty Associate professor, and bone and soft tissue surgical pathologist at Johns Hopkins University in Baltimore, Maryland. He is also one of the founding board members of the Chondrosarcoma Foundation and has been...

March 27th, 2025Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets Michael J. Wagner, MD; Erica M. Pimenta, MD, PhD1 ; Nathan W. Sweeney, PhD ; Elizabeth T. Loggers, MD, PhD; Jesse L. Roberts, MD; Elyse Brinkman, MD; Eleanor Y. Chen,...

March 18th, 2025Servier Pharmaceuticals has initiated a Phase 3 Clinical Trial for Ivosidenib, an IDH1 biomarker inhibitor. Their clinical trial is for patients diagnosed with conventional chondrosarcoma with advanced metastasis. There are about 30 sites globally...

March 7th, 2025Chondrosarcoma Patient Registry 2.0 with a new set of follow-up surveys https://chondrosarcoma.iamrare.org We are excited to announce that we’ve received IRB approval to launch a set of new surveys for patients and caregivers who completed the...

February 28th, 2025The Chondrosarcoma Foundation is proud to announce the creation of the Chondrosarcoma Tumor Board, a specialized, multidisciplinary group of medical professionals who treat chondrosarcoma. The tumor board will review cases submitted by...